Sermorelin, also known as GRF 1-29 (Growth Hormone-Releasing Factor 1-29), is a synthetic peptide analogue comprising the first 29 amino acids of endogenous human growth hormone-releasing hormone (GHRH). It represents the shortest fully active fragment of GHRH capable of stimulating growth hormone secretion from the anterior pituitary gland.
In research settings, Sermorelin acts as a GHRH receptor agonist, binding to GHRH receptors on somatotroph cells and stimulating the synthesis and pulsatile release of endogenous growth hormone. Unlike direct GH administration, Sermorelin operates through the body’s natural regulatory feedback mechanisms, making it a valuable tool for studying the hypothalamic-pituitary-somatotropic axis.
Researchers have investigated Sermorelin in the context of GH deficiency models, age-related somatotropic decline, metabolic regulation, body composition studies, and neuroendocrine function. It has also been explored in sleep-related research, given the strong correlation between GH secretion and slow-wave sleep.
Store at -20°C, protected from light and moisture. Reconstitute with bacteriostatic water prior to use in research applications.
Molecular Formula
C₁₄₉H₂₄₆N₄₄O₄₂S
Molecular Weight
3357.9 g/mol
Purity
>98%
CAS Number
86168-78-7
Form
Lyophilised Powder
Research Applications
Neuroendocrinology, Growth Hormone Deficiency Research, Hypothalamic-Pituitary Axis Studies, Metabolic and Body Composition Research, Age-Related Somatotropic Decline, Sleep Physiology Research
For research purposes only. Not for human use.
Reviews
There are no reviews yet.